专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5305126A Polymer-dispersed liquid crystal material with in-situ polymerized liquid crystal polymer grains dispersed in a layer of liquid crystal material sealed between substrates and field electrodes 失效
标题翻译：聚合物分散液晶（PDLC）装置
公开(公告)号：US5305126A
公开(公告)日：1994-04-19
申请号：US798478
申请日：1991-11-26
申请人： Hidekazu Kobayashi , Kiyohiro Samizu , Jin-Jei Wu
发明人： Hidekazu Kobayashi , Kiyohiro Samizu , Jin-Jei Wu
IPC分类号： G02F1/1333 , C09K19/38 , C09K19/54 , G02F1/1334 , G02F1/13363 , G02F1/1337 , G02F1/1347 , G02F1/139 , G02F1/133
CPC分类号： G02F1/13725 , C09K19/3852 , C09K19/542 , C09K19/544 , G02F1/1334 , G02F1/1347 , G02F2001/13345 , G02F2001/13347 , G02F2001/133638 , G02F2203/02
摘要： A polymer dispersed liquid crystal material (PDLC) device is fabricated by sealing a composite layer mixture of components comprising a polymer and liquid crystal material while both are in their liquid phase in a gap portion formed between two substrates of the device. A predetermined directional alignment is transmitted to the polymer via the liquid crystal material by means, for example, of formed directional alignment on surfaces in contact with the composite layer, such as, by deposited alignment films on a surface of at least one of the substrates. The predetermined directional alignment of the polymer is thereafter fixed by means of a polymer hardening method, such as, for example, by polymerization of a polymer precursor, so that the predetermined directional alignment of the polymer is permanently retain within the liquid crystal material, i.e., the polymer is in a solid phase and the liquid crystal material remains in its liquid phase. For better results, a chiral component and/or a light absorbing component may be added to the liquid crystal material.
摘要翻译：聚合物分散液晶材料（PDLC）装置是通过将包含聚合物和液晶材料的组分的复合层混合物密封在形成在装置的两个基板之间的间隙部分的液相中来制造的。通过例如在与复合层接触的表面上形成的定向对准，例如通过在至少一个基板的表面上沉积的取向膜，通过液晶材料将预定的定向对准传递到聚合物。然后通过聚合物硬化方法，例如通过聚合物前体的聚合来固定聚合物的预定方向排列，使得聚合物的预定方向取向永久地保持在液晶材料内，即，聚合物处于固相中，液晶材料保持在其液相中。为了更好的结果，可以向液晶材料中添加手性组分和/或光吸收组分。

2. 发明授权

US5680185A Polymer dispersed liquid crystal (PDLC) display apparatus 失效
标题翻译：聚合物分散液晶（PDLC）显示装置
公开(公告)号：US5680185A
公开(公告)日：1997-10-21
申请号：US228044
申请日：1994-04-15
申请人： Hidekazu Kobayashi , Kiyohiro Samizu , Eiji Chino , Jin Jei Wu
发明人： Hidekazu Kobayashi , Kiyohiro Samizu , Eiji Chino , Jin Jei Wu
IPC分类号： C09K19/38 , C09K19/54 , G02F1/1334 , G02F1/13363 , G02F1/139 , G02F1/136
CPC分类号： G02F1/13725 , C09K19/3852 , C09K19/542 , C09K19/544 , G02F1/1334 , G02F2001/13345 , G02F2001/133638
摘要： A polymer dispersed liquid crystal display apparatus has a liquid crystal/polymer medium formed between spatially disposed electrodes formed spatially disposed substrates. The medium includes a polymer phase and a liquid crystal phase having optical axes alignable together in a predetermined direction. A light absorption additive is included in the liquid crystal phase to provide light absorption when said optical axes are aligned in said predetermined direction so that in the presence or absence of an electric field applied between said electrodes, two different conditions are achieved comprising alignment and misalignment of the optical axes of the liquid crystal phase relative to the polymer phase so that in one condition, a light absorption state is created in the medium and in the other condition, a light scattering state is created in the medium. The polymer phase comprises a network including a plurality of continuous strings of particles connected in helicoid formation due to the addition of a chiral component, and this network may also include separate discrete polymer particles. Also a matrix network may be employed. A reflecting surface on the side of the liquid crystal/polymer medium opposite to that of incident light will enhance the light scattering and light absorbing properties in either of the two different conditions. Alternatively, the opposite side may be a white surface providing for a high contrast display with light absorption additive in the medium of dark contrast, such as, black dichroic dye.
摘要翻译：聚合物分散液晶显示装置具有形成在空间设置的电极之间形成的液晶/聚合物介质，其形成空间设置的基板。介质包括聚合物相和液晶相，其具有沿预定方向对准的光轴。当所述光轴在所述预定方向上排列时，在液晶相中包括光吸收添加剂以提供光吸收，使得在存在或不存在施加在所述电极之间的电场的情况下，实现了两个不同的条件，包括对准和未对准的液晶相的相对于聚合物相的光轴，使得在一个条件下，在介质中产生光吸收状态，而在其他条件下，在介质中产生光散射状态。聚合物相包括由于添加手性组分而连接成螺旋形状的多个连续的颗粒串的网络，并且该网络还可以包括单独的离散聚合物颗粒。也可以采用矩阵网络。在液晶/聚合物介质的与入射光相反的一侧的反射表面将增强两种不同条件下的光散射和光吸收性能。或者，相对侧可以是在黑暗对比度的介质（例如黑色二色性染料）中提供具有光吸收添加剂的高对比度显示的白色表面。

3. 发明授权

US5769393A Liquid crystal elements and method of producing same 失效
标题翻译：液晶元件及其制造方法
公开(公告)号：US5769393A
公开(公告)日：1998-06-23
申请号：US78204
申请日：1993-08-16
申请人： Hidekazu Kobayashi , Kiyohiro Samizu
发明人： Hidekazu Kobayashi , Kiyohiro Samizu
IPC分类号： C09K19/54 , G02F1/1334 , G02F1/13363 , C09K19/52 , G02F1/13
CPC分类号： C09K19/544 , G02F1/1334 , G02F2001/13345 , G02F2001/13347 , G02F2001/133638 , Y10T428/1005
摘要： A display element for use in computer terminals, television displays and other information display devices capable of large capacity, full color display employing active elements, wherein an optical layer comprises liquid crystal and polymer dispersed in one another. The polymer comprises polymer grains directionally aligned in the optical layer by directional alignment of the liquid crystal, which is aligned by treatment provided relative to at least one of the substrates forming the display element. The polymer grains are developed from the polymerization of at least one polymer precursor containing at least one polymerizable portion and at least two aromatic rings with a coupling group provided between the aromatic rings. The polymer precursor contains, as at least one component, a polymer compound without an alkyl group spacer between the polymerizable portion and the aromatic rings.
摘要翻译： PCT No.PCT / JP92 / 01367 Sec。 371日期：1993年8月16日 102（e）日期1993年8月16日PCT提交1992年10月21日PCT公布。公开号WO93 / 08497 日期：1993年04月29日用于计算机终端，电视显示器和能够大容量的其他信息显示装置的显示元件，采用有源元件的全色显示器，其中光学层包括彼此分散的液晶和聚合物。聚合物包括通过液晶的定向取向在光学层中定向取向的聚合物晶体，液晶通过相对于形成显示元件的至少一个基板提供的处理来对准。聚合物颗粒从包含至少一个可聚合部分的至少一种聚合物前体和至少两个具有在芳环之间提供的偶合基团的芳环的聚合显影出来。作为至少一种组分，聚合物前体含有在可聚合部分和芳环之间没有烷基间隔基的聚合物化合物。

4. 发明申请

US20110118311A1 AZOLE COMPOUND 有权
标题翻译： AZOLE化合物
公开(公告)号：US20110118311A1
公开(公告)日：2011-05-19
申请号：US13054057
申请日：2009-07-13
申请人： Satoshi Aoki , Ryosuke Munakata , Noriyuki Kawano , Kiyohiro Samizu , Hiromasa Oka , Takahiro Ishii , Takashi Sugane
发明人： Satoshi Aoki , Ryosuke Munakata , Noriyuki Kawano , Kiyohiro Samizu , Hiromasa Oka , Takahiro Ishii , Takashi Sugane
IPC分类号： A61K31/4545 , C07D417/14 , C07D401/14 , C07D413/14 , A61P29/00
CPC分类号： C07D401/14 , C07D413/14 , C07D417/14
摘要： A compound which is useful as an active ingredient of a pharmaceutical composition for treating neuropathic pain is provided. The present inventors have made extensive studies on compounds having an FAAH inhibitory activity, and as a result, have found that an azole compound substituted with an N-(pyridine-3-yl)oxycarbonyl-piperidin-4-yl group and a phenyl group or a pharmaceutically acceptable salt thereof has an excellent FAAH inhibitory activity, thereby completing the present invention. The compound of the present invention is confirmed to have an excellent FAAH inhibitory activity and an antiallodynic effect in rat models with neuropathic pain, and thus is useful as an agent for preventing and/or an agent for treating neuropathic pain.
摘要翻译：提供了可用作治疗神经性疼痛的药物组合物的活性成分的化合物。本发明人对具有FAAH抑制活性的化合物进行了广泛的研究，结果发现被N-（吡啶-3-基）氧基羰基 - 哌啶-4-基和苯基取代的唑化合物或其药学上可接受的盐具有优异的FAAH抑制活性，从而完成了本发明。确认本发明的化合物在具有神经性疼痛的大鼠模型中具有优异的FAAH抑制活性和抗异常性疼痛作用，因此可用作预防剂和/或治疗神经性疼痛的药剂。

5. 发明授权

US07176219B2 Salts of quinuclidine derivative 失效
标题翻译：奎宁环衍生物的盐
公开(公告)号：US07176219B2
公开(公告)日：2007-02-13
申请号：US11128238
申请日：2005-05-13
申请人： Masahiko Hayakawa , Kiyohiro Samizu , Hiroshi Uebayashi , Ken Ikeda , Makoto Takeuchi
发明人： Masahiko Hayakawa , Kiyohiro Samizu , Hiroshi Uebayashi , Ken Ikeda , Makoto Takeuchi
IPC分类号： A61K31/44
CPC分类号： C07D453/02
摘要： There is provided an acid addition salt of (−)-(3R)-quinuclidin-3-yl(1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate with an acid selected from the group consisting of (−)-(2S,3S)-tartaric acid, (+)-(2S,3S)-di-O-benzoyltartaric acid, (+)-(2S,3S)-di-O-(4-methylbenzoyl)tartaric acid, (−)-L-phenylalanine, benzenesulfonic acid, cyclohexanesulfamic acid, hydrobromic acid, naphthalene-2-sulfonic acid, sebacic acid, (+)-camphor-10-sulfonic acid, p-toluenesulfonic acid, ethanesulfonic acid, methanesulfonic acid and methyl phosphate, which has little hygroscopicity that affects the use as a drug or its drug substance, and is very useful as a drug or its drug substance.
摘要翻译：提供了（ - ） - （3R） - 奎宁环-3-基（1R）-1-苯基-1,2,3,4-四氢异喹啉-2-羧酸的酸加成盐，其中酸选自的（ - ） - （2S，3S） - 酒石酸，（+） - （2S，3S） - 二-O-苯甲酰基酒石酸，（+） - （2S，3S） - 二-O-（4-甲基苯甲酰基）酒石酸，（ - ） - L-苯丙氨酸，苯磺酸，环己烷氨基磺酸，氢溴酸，萘-2-磺酸，癸二酸，（+） - 樟脑-10-磺酸，对甲苯磺酸，乙磺酸，甲磺酸酸和磷酸甲酯，其吸湿性几乎不影响作为药物或其药物物质的用途，并且作为药物或其药物物质是非常有用的。

6. 发明授权

US08207199B2 Azole compound 有权
标题翻译：唑类化合物
公开(公告)号：US08207199B2
公开(公告)日：2012-06-26
申请号：US13054057
申请日：2009-07-13
申请人： Satoshi Aoki , Ryosuke Munakata , Noriyuki Kawano , Kiyohiro Samizu , Hiromasa Oka , Takahiro Ishii , Takashi Sugane
发明人： Satoshi Aoki , Ryosuke Munakata , Noriyuki Kawano , Kiyohiro Samizu , Hiromasa Oka , Takahiro Ishii , Takashi Sugane
IPC分类号： A61K31/4545 , C07D417/14 , C07D401/14 , C07D413/14
CPC分类号： C07D401/14 , C07D413/14 , C07D417/14
摘要： A compound which is useful as an active ingredient of a pharmaceutical composition for treating neuropathic pain is provided. The present inventors have made extensive studies on compounds having an FAAH inhibitory activity, and as a result, have found that an azole compound substituted with an N-(pyridine-3-yl)oxycarbonyl-piperidin-4-yl group and a phenyl group or a pharmaceutically acceptable salt thereof has an excellent FAAH inhibitory activity, thereby completing the present invention. The compound of the present invention is confirmed to have an excellent FAAH inhibitory activity and an antiallodynic effect in rat models with neuropathic pain, and thus is useful as an agent for preventing and/or an agent for treating neuropathic pain.
摘要翻译：提供了可用作治疗神经性疼痛的药物组合物的活性成分的化合物。本发明人对具有FAAH抑制活性的化合物进行了广泛的研究，结果发现被N-（吡啶-3-基）氧基羰基 - 哌啶-4-基和苯基取代的唑化合物或其药学上可接受的盐具有优异的FAAH抑制活性，从而完成了本发明。确认本发明的化合物在具有神经性疼痛的大鼠模型中具有优异的FAAH抑制活性和抗异常性疼痛作用，因此可用作预防剂和/或治疗神经性疼痛的药剂。

7. 发明申请

US20060205770A1 NOVEL SALTS OF QUINUCLIDINE DERIVATIVE 失效
标题翻译：喹诺酮衍生物的新型盐
公开(公告)号：US20060205770A1
公开(公告)日：2006-09-14
申请号：US11128238
申请日：2005-05-13
申请人： Masahiko Hayakawa , Kiyohiro Samizu , Hiroshi Uebayashi , Ken Ikeda , Makoto Takeuchi
发明人： Masahiko Hayakawa , Kiyohiro Samizu , Hiroshi Uebayashi , Ken Ikeda , Makoto Takeuchi
IPC分类号： C07D453/02 , A61K31/4745
CPC分类号： C07D453/02
摘要： There is provided an acid addition salt of (−)-(3R)-quinuclidin-3-yl(1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate with an acid selected from the group consisting of (−)-(2S,3S)-tartaric acid, (+)-(2S,3S)-di-O-benzoyltartaric acid, (+)-(2S,3S)-di-O-(4-methylbenzoyl)tartaric acid, (−)-L-phenylalanine, benzenesulfonic acid, cyclohexanesulfamic acid, hydrobromic acid, naphthalene-2-sulfonic acid, sebacic acid, (+)-camphor-10-sulfonic acid, p-toluenesulfonic acid, ethanesulfonic acid, methanesulfonic acid and methyl phosphate, which has little hygroscopicity that affects the use as a drug or its drug substance, and is very useful as a drug or its drug substance.
摘要翻译：提供了（ - ） - （3R） - 奎宁环-3-基（1R）-1-苯基-1,2,3,4-四氢异喹啉-2-羧酸的酸加成盐，其中酸选自的（ - ） - （2S，3S） - 酒石酸，（+） - （2S，3S） - 二-O-苯甲酰基酒石酸，（+） - （2S，3S） - 二-O-（4-甲基苯甲酰基）酒石酸，（ - ） - L-苯丙氨酸，苯磺酸，环己烷氨基磺酸，氢溴酸，萘-2-磺酸，癸二酸，（+） - 樟脑-10-磺酸，对甲苯磺酸，乙磺酸，甲磺酸酸和磷酸甲酯，其吸湿性几乎不影响作为药物或其药物物质的用途，并且作为药物或其药物物质是非常有用的。

8. 发明申请

US20050090498A1 3-Quinolin-2(1h)-ylideneindolin-2-one derivative 审中-公开
标题翻译： 3-喹啉-2（1h） - 亚基二氢吲哚-2-酮衍生物
公开(公告)号：US20050090498A1
公开(公告)日：2005-04-28
申请号：US10478504
申请日：2002-05-23
申请人： Kiyohiro Samizu , Hiroyuki Hisamichi , Akira Matsuhisa , Isao Kinoyama , Masahiko Hayakawa , Nobuaki Taniguchi , Yukitaka Ideyama , Sadao Kuromitsu , Kiyoshi Yahiro , Minoru Okada
发明人： Kiyohiro Samizu , Hiroyuki Hisamichi , Akira Matsuhisa , Isao Kinoyama , Masahiko Hayakawa , Nobuaki Taniguchi , Yukitaka Ideyama , Sadao Kuromitsu , Kiyoshi Yahiro , Minoru Okada
IPC分类号： A61P27/02 , A61P35/00 , A61P43/00 , C07D209/34 , C07D211/22 , C07D215/12 , C07D215/60 , C07D263/10 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D491/10 , C07D491/113 , C07D493/04 , C07D471/02 , A61K31/4709 , A61K31/4745 , A61K31/498 , A61K31/519
CPC分类号： C07D263/10 , C07D209/34 , C07D211/22 , C07D215/12 , C07D215/60 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D491/10 , C07D493/04
摘要： There is provided medicaments, particularly a vascular endothelial growth factor (VEGF) inhibitor which is useful as a therapeutic drug for solid tumors, diabetic retinopathy and the like diseases in which angiogenesis is taking a role. That is, since a novel 3-quinolin-2(1H)-ylideneindolin-2-one derivative or a salt thereof has good VEGF inhibitory action, angiogenesis inhibitory action and anti-tumor action, it is useful as ideal VEGF inhibitor, angiogenesis inhibitor and anti-tumor agent.
摘要翻译：提供了药物，特别是血管内皮生长因子（VEGF）抑制剂，其可用作实体瘤的治疗药物，糖尿病性视网膜病变等血管生成正在起作用的疾病。也就是说，由于新型3-喹啉-2（1H） - 亚基二氢吲哚-2-酮衍生物或其盐具有良好的VEGF抑制作用，血管生成抑制作用和抗肿瘤作用，因此可用作理想的VEGF抑制剂，血管生成抑制剂和抗肿瘤剂。

9. 发明授权

US06673799B1 Cyanophenyl derivative 失效
标题翻译：氰基苯基衍生物
公开(公告)号：US06673799B1
公开(公告)日：2004-01-06
申请号：US09787672
申请日：2001-03-21
申请人： Nobuaki Taniguchi , Isao Kinoyama , Takashi Kamikubo , Akira Toyoshima , Kiyohiro Samizu , Eiji Kawaminami , Masakazu Imamura , Hiroyuki Moritomo , Akira Matsuhisa , Masaaki Hirano , Yoji Miyazaki , Eisuke Nozawa , Minoru Okada , Hiroshi Koutoku , Mitsuaki Ohta
发明人： Nobuaki Taniguchi , Isao Kinoyama , Takashi Kamikubo , Akira Toyoshima , Kiyohiro Samizu , Eiji Kawaminami , Masakazu Imamura , Hiroyuki Moritomo , Akira Matsuhisa , Masaaki Hirano , Yoji Miyazaki , Eisuke Nozawa , Minoru Okada , Hiroshi Koutoku , Mitsuaki Ohta
IPC分类号： C07D23174
CPC分类号： C07D295/192 , C07D213/85 , C07D241/08 , C07D295/205 , C07D295/215 , C07D295/26
摘要： This application relates to a piperazino-substituted novel cyanophenyl derivative in which a substituted carbamoyl or substituted sulfamoyl group having an aryl, heterocyclic or the like group that may have a substituent group is bonded to one nitrogen atom on the piperazine ring. The compound of this application has an anti-androgen action and is useful in preventing or treating prostatic cancer, benign prostatic hyperplasia and the like diseases.
摘要翻译：本申请涉及哌嗪取代的新型氰基苯基衍生物，其中具有可具有取代基的芳基，杂环等基团的取代氨基甲酰基或取代氨磺酰基与哌嗪环上的一个氮原子键合。本申请的化合物具有抗雄激素作用，可用于预防或治疗前列腺癌，良性前列腺增生等疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式